Bank of America maintains a 'buy' rating on Merck, anticipating a potential share re-rating driven by upcoming clinical trial data in oncology and other pipeline areas over the next 12 to 18 months. Key focus includes Phase 3 results for SAC-TMT in lung cancer and data on intismeran, a personalized cancer vaccine developed with Moderna, with important presentations expected at the European Society for Medical Oncology meeting. Merck's management is confident in the pipeline's potential, including new programs in ophthalmology and treatments targeting unmet medical needs, supporting the positive investment outlook.
As of Sep 24, 2026 01:41 WIB, Merck & Co., Inc. (MRK) trades at USD 147.56 on Pluang, showing a 1-day decline of 2.23%. The stock sees a strong buying interest with 73% of order activity on the platform favoring buys over sells. Despite the recent dip, the company maintains a substantial market cap of $372.32 billion, highlighting its significant presence in the health sector.
Moderna's stock surged 5% to $181.51, marking a 516% gain in 2026, driven by anticipation of late-October Phase 3 data for its personalized cancer therapy, intismeran autogene, developed with Merck. The therapy targets high-risk melanoma patients and...
The Invesco S&P 500 Momentum ETF (SPMO) underwent a semi-annual reconstitution, resulting in 54 changes affecting about 40% of its portfolio. Apple and Merck were the largest additions, while Nvidia was removed despite a strong one-year gain of over ...
Moderna's shares surged 9% after its Phase 3 melanoma study was selected for a prestigious Presidential Symposium slot at the European Society for Medical Oncology congress. This high-profile placement signals strong confidence in the study's potenti...
